A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.

NCT05231850 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

70

Enrollment

OTHER

Sponsor class

Conditions

Colon Cancer

Interventions

DRUG: Tislelizumab

Sponsor

The First Affiliated Hospital of Zhengzhou University